ABSI Absci Corporation
USHealthcareAs of 2026-07-09 16:00
Why ABSI matters now
Absci Corporation (ABSI) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.47 with +3.33% on the session and $1.94B in market capitalization; recent performance reads 1-month +60.04% and YTD +112.32%.
The latest financial table shown here is Q1 2026, with revenue of $215.0K, net income of $-29.6M, and EPS of $-0.19. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8.5%.
The latest indexable market news headline is "Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.50; recent insider activity includes Szela Mary T filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.59
P/S
629.22
EV/EBITDA
-10.77
DCF Value
$0.04
FCF Yield
-8.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1316.9%
Operating Margin
-7000.8%
Net Margin
-6450.8%
ROE
-63.6%
ROA
-60.6%
ROIC
-72.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $215.0K | $-29.6M | $-0.19 |
| Q4 2025 | $650.0K | $-29.6M | $-0.20 |
| FY 2025 | $2.8M | $-115.2M | $-0.84 |
| Q3 2025 | $378.0K | $-28.7M | $-0.20 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.03
Target (Median)
$10.50
Target Range
$4.10 - $15.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.46
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.